Virax Biolabs Group (NASDAQ:VRAX) was upgraded by analysts at Zacks Research to a "hold" rating.
Virax Biolabs Group (NASDAQ:VRAX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Virax Biolabs Group (NASDAQ:VRAX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $1.00 price target on the stock, down previously from $3.00.
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement [Yahoo! Finance]
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement